Modern Vaccine Trial: How Optimistic Coronavirus News Driven Stock Increase


When the modern biotech company announced positive results Monday morning of a small preliminary trial of its coronavirus vaccine, the company's chief medical officer described the news as "a triumphant day for us."

Moderna's share price rose as much as 30 percent. His announcement helped lift the stock market and was widely reported by news organizations, including The New York Times.

Nine hours after its initial news release, and after the markets closed, the company announced a stock offering with the goal of raising more than $ 1 billion to help develop vaccines to fund. That offer had not been mentioned in Moderna's investor and journalist briefings that morning, and the company's president later said it was decided that afternoon.


Please enter your comment!
Please enter your name here